ENSYSCE BIOSCIENCES INC (ENSC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.36-2.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ENSC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -87.6% |
| Our one-year growth estimate | diamond | -34.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 52.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
ENSC — CEO transition
Dated 2026-11-04
CEO — Dr. Lynn Kirkpatrick: The CEO is transitioning to the role of COO with a named internal successor (President James Morrisson) taking over the CEO title, indicating an orderly succession rather than a sudden loss of leadership.
Why it matters: The vote is needed to convert Series C preferred shares into common shares. The result will settle a key part of the financing terms.
Watch forStockholders approve the proposal to convert Series C at the meeting.
Also watch forStockholders reject the proposal, or the company reports that the vote did not pass.
Why it matters: CY200 is the new lead program. Trial start and enrollment will show whether the company is moving its plan into action.
Supportive ifThe company names a Phase 2 start date and reports that the first patient has enrolled in the CRPS Type 1 trial.
Worry ifThe next company update reports that the Phase 2 start or first enrollment has slipped, or gives no trial start window.
Why it matters: The added funds depend on a clinical milestone. Reaching it would support more CY200 work and extend the stated cash runway.
Supportive ifAn 8-K or company release confirms the clinical milestone was met. It also confirms the follow-on financing tranche closed.
Worry ifThe company says the milestone was missed or the tranche did not close. It may also say the planned follow-on funds are no longer available.
Why it matters: The company reported cash of $0.7 million at June 30, before later deal funding. The next results can show cash use and program progress.
Worry ifThe Nov. 13 report shows cash below the stated runway plan, rising operating cash use, or a delay in a named clinical program.
Less concerning ifThe report confirms cash runway into late 2027 or later and continued progress on CY200 and PF614-MPAR.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$321 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $1,194 loss on $10,000 · 11.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,793 loss on $10,000 · 87.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: CY200 has no approved treatment for CRPS Type 1 to compete against. Clear trial results would test the new lead program.
Supportive ifThe company reports Phase 2 results. They show symptom relief and acceptable safety and tolerability, in line with the trial's stated goals.
Worry ifThe company reports that the trial misses its stated symptom goals or finds safety concerns. Topline data may also arrive after its stated window.